newsfilter
← Latest News
GlobeNewswire·

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21